Hosted on MSN1d
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...
lupus.bmj3d
Intermediate monocytes in blood correlate with subclinical vascular changes in lupus nephritis
Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...
The Pharma Letter2d
NEJM publishes key Gazyva data in lupus nephritis
Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...
Pharm Exec3d
FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
FierceBiotech2d
Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...
Genentech publishes REGENCY trial data in the New England Journal of Medicine
Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...
Too Old to Operate6d
Longitudinal Study of Genetic Risk in Renal and Non-Renal Lupus
The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...
Too Old to Operate6d
Predicting Proliferative LN in Patients With Low-Level Proteinuria
The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...
PharmiWeb2d
New England Journal of Medicine publishes new data…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...